Works matching IS 11738804 AND DT 2019 AND VI 33 AND IP 1
Results: 12
FKB327: An Adalimumab Biosimilar.
- Published in:
- BioDrugs, 2019, v. 33, n. 1, p. 113, doi. 10.1007/s40259-019-00335-8
- By:
- Publication type:
- Article
Pegfilgrastim-jmdb/MYL-1401H: A Pegfilgrastim Biosimilar.
- Published in:
- BioDrugs, 2019, v. 33, n. 1, p. 117, doi. 10.1007/s40259-019-00334-9
- By:
- Publication type:
- Article
Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases.
- Published in:
- BioDrugs, 2019, v. 33, n. 1, p. 15, doi. 10.1007/s40259-019-00333-w
- By:
- Publication type:
- Article
Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial.
- Published in:
- BioDrugs, 2019, v. 33, n. 1, p. 79, doi. 10.1007/s40259-018-00331-4
- By:
- Publication type:
- Article
Comment on “The End of Phase 3 Clinical Trials in Biosimilars Development?”.
- Published in:
- BioDrugs, 2019, v. 33, n. 1, p. 121, doi. 10.1007/s40259-018-0330-1
- By:
- Publication type:
- Article
Current Ebola Virus Vaccine Progress.
- Published in:
- BioDrugs, 2019, v. 33, n. 1, p. 9, doi. 10.1007/s40259-018-0329-7
- By:
- Publication type:
- Article
The Impact of the Fecal Microbiome on Cancer Immunotherapy.
- Published in:
- BioDrugs, 2019, v. 33, n. 1, p. 1, doi. 10.1007/s40259-018-0328-8
- By:
- Publication type:
- Article
Monoclonal Antibodies for Multiple Sclerosis: An Update.
- Published in:
- BioDrugs, 2019, v. 33, n. 1, p. 61, doi. 10.1007/s40259-018-0327-9
- By:
- Publication type:
- Article
A Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of Proposed Biosimilar GB242 and Reference Infliximab in Healthy Subjects.
- Published in:
- BioDrugs, 2019, v. 33, n. 1, p. 93, doi. 10.1007/s40259-018-0326-x
- By:
- Publication type:
- Article
Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies.
- Published in:
- BioDrugs, 2019, v. 33, n. 1, p. 33, doi. 10.1007/s40259-018-0325-y
- By:
- Publication type:
- Article
Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities.
- Published in:
- BioDrugs, 2019, v. 33, n. 1, p. 45, doi. 10.1007/s40259-018-0324-z
- By:
- Publication type:
- Article
Comparison of the Pharmacokinetic-Pharmacodynamic Relationships of Two Darbepoetin Alfa Formulations in Healthy Male Volunteers.
- Published in:
- BioDrugs, 2019, v. 33, n. 1, p. 101, doi. 10.1007/s40259-018-0323-0
- By:
- Publication type:
- Article